Abstract: Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.

Abstract: Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.

Abstract: The present disclosure relates, at least in part, to mycobacterial polynucleotides and polypeptides, to fragments or variants thereof, to cells comprising the mycobacterial polynucleotides and polypeptides, to cells comprising the mycobacterial polynucleotides and polypeptides, that are engineered to expand T-cells ex vivo, and to methods of use thereof.

Abstract: The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.

Abstract: The invention pertains to a method for treating a cancer which expresses PRAME using T cells which recognize specific peptide epitopes of PRAME, to a method for producing T cells that target cancer cells expressing PRAME, the peptide epitopes of PRAME themselves and to compositions and methods of treatment using these peptides.

Abstract: Disclosed are compositions of cells, libraries of such cells and methods of making T cell populations for treatment of disorders such as cancer and viral infections. T cell composition comprise cell subpopulations stimulated, in some embodiments, with FRAME, survivin and/or WT1.

Abstract: The present disclosure relates to thermal management of wireless access points including local thermal management, cloud-based thermal management, and thermal management based on optimization and operation such as in a distributed Wi-Fi network. The objective of the present disclosure is for thermal management in access points allowing small form-factors and aesthetic designs, preventing overheating and without requiring reduced performance or reduced hardware. Generally, the systems and methods detect when access points are nearing overheating and alter their operation so as to minimize the reduction of performance in the network while reducing power consumption.

Abstract: The disclosure relates to methods of culturing and expanding CD4+ and/or CD8+ T cells in culture. In some embodiments, the methods include expanding, proliferating and storing lymphocytes in tissue culture by exposing the lymphocytes to a combination of cytokines and/or nucleic acids expressing cytokines or functional fragments or variants thereof. The disclosure further relates to methods of generating and manufacturing CD4+ and/or CD8+ T cells that are specific to one or a plurality of viral antigens.

Abstract: Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD 138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.

Abstract: The disclosure provides T-cell compositions, therapies and processes of manufacture that are tailored to the specific antigenic expression of a subjects' tumor and allowing for changes in expression over time based on either pressure from antineoplastic therapy or natural heterogeneous selection. The disclosure also extends to methods of manufacturing such T-cell compositions and the generation of single antigen T-cell banks from healthy donors to provide an improved personalized T-cell therapy.

Abstract: Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.

Abstract: The present disclosure relates, at least in part, to a closed and semi-automated system for the isolation of naive T cells, their expansion, and/or final harvest. The disclosure also relates to using those isolated cells in a large batch format for compiling stocks of stimulated CD45A+ T cells and/or using the stimulated CD45A+ T cells for therapeutic purposes.

Abstract: The present disclosure relates, at least in part, to mycobacterial polynucleotides and polypeptides, to fragments or variants thereof, to cells comprising the mycobacterial polynucleotides and polypeptides, to cells comprising the mycobacterial polynucleotides and polypeptides, that are engineered to expand T-cells ex vivo, and to methods of use thereof.

Abstract: Safe, rapid and efficient methods for producing virus-specific or other antigen-specific T-cells from cord blood and other samples containing naive immune cells.

Abstract: The present disclosure provides for isolated and processed cell therapeutic compositions and Methods of using those compositions for the treatment of a patient undergoing a hematopoietic stem cell transplant (HSCT). In some embodiments, the disclosure provides for methods of making these cells by exposing the isolated T cell populations to one or more tumor antigens.

Abstract: The present invention provides isolated cell compositions for the treatment of cancer, including hematological and solid tumors, comprising a selected, fixed ratio of multiple ex vivo activated lymphocytic cell subsets, including specific immune effector cells directed to specific tumor associated antigens (TAAs), viral associated tumor antigens (VATA), glycolipids, or a combination thereof. By selecting specific fixed ratios of different lymphocytic cell subsets, an immune response which is comprehensive and broad pin biological and immune effector function is provided, enhancing the ability of the administered cells to mount an effective and robust immune response.

Abstract: The present disclosure relates to thermal management of wireless access points including local thermal management, cloud-based thermal management, and thermal management based on optimization and operation such as in a distributed Wi-Fi network. The objective of the present disclosure is for thermal management in access points allowing small form-factors and aesthetic designs, preventing overheating and without requiring reduced performance or reduced hardware. Generally, the systems and methods detect when access points are nearing overheating and alter their operation so as to minimize the reduction of performance in the network while reducing power consumption.

Abstract: Systems and methods of cloud-based thermal control of an access point performed by a cloud-based controller include periodically obtaining temperature measurements from the access point comprising one or more radio chips operating therein; responsive to the temperature exceeding a first threshold, causing one or more thermal mitigation techniques to modify operating conditions of the one or more radio chips; and, responsive to the temperature being lower than a second threshold, causing reversion back of the one or more thermal mitigation techniques.

Abstract: An antenna system reusing metallic components in a device includes a first antenna element which is also configured to transfer heat into surrounding air; a ground plane which is part of reused metallic components in the device for heat dissipation; and a first physical connection between the first antenna element and the ground plane which supports thermal conductivity based on an associated size and material of the first physical connection.

Abstract: Systems and methods of local thermal control of an access point include determining temperature associated with the access point including one or more radio chips operating therein; responsive to the temperature exceeding a first threshold, performing one or more thermal mitigation techniques to modify operating conditions of the one or more radio chips; and, responsive to the temperature being lower than a second threshold, reverting back the one or more thermal mitigation techniques.